A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth

Molecular Cancer Therapeutics

Volumn 7, Issue 11, 2008, Pages 3598-3608

  Greenberger, Lee M ^a   Horak, Ivan D ^a   Filpula, David ^a   Sapra, Puja ^a   Westergaard, Majken ^b   Frydenlund, Henrik F ^b   Albæk, Charlotte ^b   Schrøder, Henrik ^b   Ørum, Henrik ^b  

^a Enzon Incorporated   (United States)

^b Santaris Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EZN 2968; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; NUCLEIC ACID; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OLIGONUCLEOTIDES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 56249131779     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0510     Document Type: Article

References (45)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-43.
3. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72.
4. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3:e47.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
6. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
7. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82.
8. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 2007;117:862-5.
9. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-4.
10. Chandel NS, Maltepe E, Goldwasser E, et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A 1998;95:11715-20.
11. Lin X, David CA, Donnelly JB, et al. A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A 2008;105:174-9.
12. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.
13. Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF1-a to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247-55.
14. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
15. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 2002;39:178-83.
16. Pollard PJ, Spencer-Dene B, Shukla D, et al. Targeted inactivation of FH1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 2007;11:311-9.
17. Ratcliffe PJ. Fumarate hydratase deficiency and cancer: activation of hypoxia signaling? Cancer Cell 2007;11:303-5.
18. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007;12:853-9.
19. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4:601-5.
20. Semenza GL. Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets 2006;10:267-80.
21. Li L, Lin X, Staver M, et al. Evaluating hypoxia-inducible factor-1α as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005;65:7249-58.
22. Bernardi R, Guernah I, Jin D, et al. PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR. Nature 2006;442:779-85.
23. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
24. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004;6:33-43.
25. Koh MY, Spivak-Kroizman T, Venturini S, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1a. Mol Cancer Ther 2008;7:90-100.
26. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006;126:231-5.
27. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-79.
28. Koch T, Orum H. Locked nucleic acid. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. Florida: CRC Press; 2008. p. 519-65.
29. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004;43:13233-41.
30. Dean NM, McKay R, Condon TP, Bennett CF. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem1994;269:16 416-24.
31. Tang N, Wang L, Esko J, et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485-95.
32. Venetsanakos E, Mirza A, Fanton C, et al. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp Cell Res 2002;273:21-33.
33. Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G. Hypoxic induction of an HIF-1α-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 2006;107:2705-12.
34. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1α in clear cell renal cell carcinoma. Clin Cancer Res 2007;13:7388-93.
35. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1178-82.
36. MacLachlan I. Liposomal formulations for nucleic acid delivery. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. Florida: CRC Press. p. 237-70.
37. Henke E, Perk J, Vider J, et al. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 2008;26:91-100.
38. Butler M, Stecker K, Bennett CF. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 1997;77:379-88.
39. Graham MJ, Crooke ST, Monteith DK, et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 1998;286:447-58.
40. Kietzmann T, Cornesse Y, Brechtel K, Modaressi S, Jungermann K. Perivenous expression of the mRNA of the three hypoxia-inducible factor α-subunits, HIF1α, HIF2α and HIF3α, in rat liver. Biochem J 2001;354:531-7.
41. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9.
42. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
43. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007;12:1404-15.
44. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48 Suppl 1:S20-37.
45. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-37.